161 First Street
About SigilonSigilon Therapeutics was founded and created by Flagship Pioneering. Sigilon Therapeutics is developing treatments for chronic diseases using new biomaterials, developed at the Massachusetts Institute of Technology (MIT), that can shield implanted cells from immune attack. Treatments based on Sigilon Therapeutics' technology platform include cell implants that act as responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.
Scientific Founders: Bob Langer and Daniel Anderson
CEO: Paul Wotton
CTO: David Peritt, Ph.D.
CBO: James D. Watson
Please click here for Sigilon Therapeutics' job opportunities.
Please click here for Sigilon Therapeutics technology.
Please click here for Sigilon Therapeuticss pipeline.
12 articles with Sigilon
Portfolio Covers 16 Patent Families Across Major Markets
Two members of its executive leadership team will present at the 2018 Cell & Gene Meeting on the Mesa in La Jolla, California.
Sigilon Therapeutics Announces Leadership Transition and Appoints Rare Disease Pioneer Rogerio Vivaldi, M.D., as Chief Executive Officer
Sigilon Therapeutics announced that Rogerio Vivaldi, M.D., has joined the company as Chief Executive Officer.
8/14/2018A little more than one year after Flagship Pioneering launched Sigilon Therapeutics, the company has a new chief executive officer. This morning Sigilon announced Bioverativ veteran Rogerio Vivaldi will helm the Cambridge, Mass.-based company.
Sigilon Therapeutics announced that the company will present at the GTCbio 15th Stem Cell Summit being held April 12-13, 2018, in Boston. Presentation details are as follows:
Less than one year after it launched Cambridge, Mass.-based startup Sigilon Therapeutics struck a collaboration deal with Eli Lilly to develop encapsulated cell therapies for the potential treatment of type 1 diabetes.
Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes
Sigilon's Afibromer technology will be used to encapsulate insulin-producing cells for the potential treatment of type 1 diabetes
Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the following upcoming conference
Sigilon Therapeutics Receives Advanced Therapy Medicinal Product Designation for Afibromer™-Based Living Therapeutic Program
Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that its Afibromer™ Living Therapeutic candidate SIG-003 has been granted an Advanced Therapy Medicinal Product (ATMP) designation by the Committee for Advanced Therapies of the European Medicines Agency.
Dr. Moller brings a long history of experience in drug discovery and development to the company, including a focus on development of therapeutics for metabolic disorders and in the identification and evaluation of emerging technologies.
Sigilon today announced the appointment of Eric Shaff, CFO of Seres, to the Sigilon board of directors.